Skip to main content

Advertisement

SpringerLink
Log in

Management of Pediatric and Adult Patients with Medulloblastoma

  • Neuro-oncology (GJ Lesser, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

Approximately 70 % of newly diagnosed children with medulloblastoma (MB) will be classified as “standard risk”: their tumor is localized to the posterior fossa, they undergo a near or gross total resection, the tumor does not meet the criteria for large cell/anaplastic histology, and there is no evidence of neuroaxis dissemination by brain/spine MRI and lumbar puncture for cytopathology. Following surgical recovery, they are treated with craniospinal radiation therapy with a boost to the posterior fossa or tumor bed. Adjuvant therapy for approximately 1 year follows anchored by the use of alkylators, platinators, and microtubule inhibitors. This approach to standard risk MB works; greater than 80 % of patients will be cured, and such approaches are arguably the standard of care worldwide for such children. Despite this success, some children with standard risk features will relapse and die of recurrent disease despite aggressive salvage therapy. Moreover, current treatment, even when curative causes life-long morbidity in those who survive, and the consequences are age dependent. For the 20-year-old patient, damage to the cerebellum from surgery conveys greater risk than craniospinal radiation; however, for the 3-year-old patient, the opposite is true. The challenge for the neuro-oncologist today is how to identify accurately patients who need less therapy as well as those for whom current therapy is inadequate. As molecular diagnostics comes of age in brain tumors, the question becomes how to best implement novel methods of risk stratification. Are we able to obtain specific information about the tumor’s biology in an increasingly rapid and reliable way, and utilize these findings in the upfront management of these tumors? Precision medicine should allow us to tailor therapy to the specific drivers of each patient’s tumor. Regardless of how new approaches are implemented, it is likely that we will no longer be able to have a single standard approach to standard risk medulloblastoma in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neuroectodermal tumours in adults and children. J Clin Neurosci. 2012;19:1541–4.

    Article  PubMed  Google Scholar 

  2. Bailey P, Cushing H. Medulloblastoma cerebelli, a common type of mid-cerebellar glioma of childhood. Arch Neurol Psychiatry. 1999;14:192–224.

    Article  Google Scholar 

  3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon: IARC; 2007. p. 1–309.

    Google Scholar 

  4. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas. Cancer. 2002;94(2):552–60.

    Article  PubMed  Google Scholar 

  6. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408–14. This paper is the first to describe the molecular subgroups as they are now accepted.

    Article  PubMed  Google Scholar 

  7. Taylor M, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:464–72. This paper provides a consensus guideline for the clinical significance of the molecular subgroups and also provides a great overview of this topic.

    Article  Google Scholar 

  8. Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014;32(9):886–96. Proposes a potential way to identify molecular subgroups in real time to be incorporated into patient care.

    Article  PubMed  Google Scholar 

  9. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121:381–96.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202–8. Even though this is an older study it provides the backbone for current standard risk therapy in medulloblastoma. Due to smaller sample sizes pediatric trials are slower to complete.

    Article  PubMed  CAS  Google Scholar 

  11. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the children’s cancer group 921 randomized phase III study. J Clin Oncol. 1999;17(3):832.

    PubMed  CAS  Google Scholar 

  12. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81:690–8.

    Article  PubMed  CAS  Google Scholar 

  13. Packer RJ, Zhou T, Holmes E, et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of children’s oncology group trial A9961. Neuro-Oncology. 2013;15(1):97–103. The first long-term follow-up study to document comparable survival in patients treated with therapy nearly equivalent to the current standard.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Tarbell NJ, Friedman H, Polkinghorn WR, et al. High risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiaton therapy (POG 9031). J Clin Oncol. 2013;31(23):2936–41.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ashley DM, Merchant TE, Strother D, et al. Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: children’s oncology group study P9934. J Clin Oncol. 2012;30(26):3181–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Von Bueren AO, von Hoff K, Torsten P, et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology. 2011;13(6):669–79.

    Article  Google Scholar 

  17. Gopalakrishnan CV, Dhakoji A, Menon G, et al. Factors predicting the need for cerebrospinal fluid diversion following posterior fossa tumor surgery in children. Pediatr Neurosurg. 2012;48(2):93–101.

    Article  PubMed  CAS  Google Scholar 

  18. Albright AL, Wisoff JH, Zeltzer PM, et al. Effects of medulloblastoma resections on outcome in children: a report from the children’s cancer group. Neurosurgery. 1996;38(2):265–71.

    Article  PubMed  CAS  Google Scholar 

  19. Robertson PL, Muraszko KM, Holmes EJ, et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the children’s oncology group. J Neurosurg Pediatr. 2006;105:444–51. The only prospective study on cerebellar mutism.

    Article  Google Scholar 

  20. Kortman RD, Kuhl J, Timmerman B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ’91. Int J Radiat Oncol Biol Phys. 2000;46(2):269–79.

    Article  Google Scholar 

  21. Polkinghorn WR, Dukel IJ, Souweidane MM, et al. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. Int J Radiat Oncol Biol Phys. 2011;81(3):1–6.

  22. Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer. 2008;50(6):1169–75.

    Article  PubMed  Google Scholar 

  23. Groll AH, Ritter J, Müller FM. Guidelines for prevention of pneumocystis Carinii pneumonitis in children and adolescents with cancer. Klin Padiatr. 2001;213:A38–49.

    Article  PubMed  Google Scholar 

  24. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of proton therapy. Cancer Treat Rev. 2009;35(1):79–96.

    Article  PubMed  CAS  Google Scholar 

  25. Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc Natl Acad Sci. 2013;110(50):20224–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Lin TL, Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in development. OncoTargets Ther. 2012;5:47–58.

    Article  CAS  Google Scholar 

  27. Kool M, Jones DT, Jäger N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25(3):393–405.

    Article  PubMed  CAS  Google Scholar 

  28. Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Neuropathol Appl Neurobiol. 2014;12(13):1229–39.

  29. Chung CS, Keating N, Yock T, et al. Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy. Int J Radiat Oncol Biol Phys. 2008;72:S8.

    Article  Google Scholar 

  30. Yuh GE, Loredo LN, Yonemoto LT, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J. 2004;10(6):386–90.

    Article  PubMed  Google Scholar 

  31. Wolden SL. Protons for craniospinal radiation: are clinical data important? Int J Radiat Oncol Biol Phys. 2013;87(2):231–2.

    Article  PubMed  Google Scholar 

  32. Friedrich C, von Bueren AO, von Hoff K, et al. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. Eur J Cancer. 2013;49(4):893–903.

    Article  PubMed  Google Scholar 

  33. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammineplatinum (II) in Man. Cancer Treat Rep. 1979;63:1527–31.

    Google Scholar 

  34. McHaney VA, Thibadoux G, Hayes FA, et al. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr. 1983;102:314–7.

    Article  PubMed  CAS  Google Scholar 

  35. Hows JM, Mehta A, Ward L, et al. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. Br J Cancer. 1984;50:753–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Kenney LB, Laufer MR, Grant FD, et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91:613–21.

    Article  PubMed  CAS  Google Scholar 

  37. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther. 1991;52:35–84.

    Article  PubMed  CAS  Google Scholar 

  38. Green DM, Zevon MA, Reese PA, et al. Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol. 1994;22(1):1–10.

    Article  PubMed  CAS  Google Scholar 

  39. Legha SS. Vincristine neurotoxicity. Med Toxicol. 1986;1(6):421–7.

    PubMed  CAS  Google Scholar 

  40. Tabori U, Sung L, Hukin J, et al. Canadian pediatric brain tumor consortium. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian pediatric brain tumor consortium study. Cancer. 2005;103(9):1874–80.

    Article  PubMed  Google Scholar 

  41. Brandes AA, Ermani M, Amista P, et al. The treatment of adults with medulloblastoma: a prospective study. Int J Radiat Oncol Biol Phys. 2003;57(3):755–61.

    Article  PubMed  Google Scholar 

  42. Ross SG, Northman L, Morris M, et al. Cerebellar mutism after posterior fossa tumor resection case discussion and recommendations for psychoeducational intervention. J Pediatr Oncol Nurs. 2014;31(2):78–83.

    Article  PubMed  Google Scholar 

  43. Pizer BL, Clifford SC. The potential impact or tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg. 2009;23(4):364–75.

    Article  PubMed  Google Scholar 

  44. Goschzik T, zur Mühlen A, Kristiansen G, et al. Molecular Stratification of Medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumors. Pediatr Blood Cancer. 2010;54(4):519-25

  45. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhinition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461(7264):614–20.

    Article  PubMed  CAS  Google Scholar 

  46. Castellone MD, Teramoto H, Williams BO, et al. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005;310(5753):1504–10.

    Article  PubMed  CAS  Google Scholar 

  47. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71(2):435–44.

    Article  PubMed  CAS  Google Scholar 

  48. Kim J, Lee JJ, Gardner D, et al. Arsenic antagonizes the hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107(30):13432–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  49. Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking hedgehog/GLI pathway. J Clin Investig. 2011;121(1):148–60.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  50. Raabe E, Eberhart CG. Therapeutic targeting of developmental signaling pathways in medulloblastoma: hedgehog, notch, Wnt and Myc. Curr Signal Transduct Ther. 2013;8:1–12.

    Article  Google Scholar 

  51. Shalaby T, von Bueren AO, Hurlimann ML, et al. Disabling c-MYC in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadraplex interactive agent S2T1-6OTD. Mol Cancer Ther. 2010;9(1):167–79.

    Article  PubMed  CAS  Google Scholar 

  52. Je D, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–17.

    Article  Google Scholar 

  53. Li XN, Shu Q, Su JM, et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther. 2005;4(12):1912–22.

    Article  PubMed  CAS  Google Scholar 

  54. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488(7409):49–56.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  55. Ardon H, De Vleeschower S, Van Calenbergh F, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Cancer Immun 2008;8(7):54519–525.

  56. Oba-Shinjo SM, Caballero OL, Jungbluth AA, et al. Cancer-testis (CT) antigen expression in medulloblastoma. J Clin Oncol. 2005;23(24):5511-9.

  57. Ahmed N, Ratnayake M, Savoldo B, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007;67:5957–64.

    Article  PubMed  CAS  Google Scholar 

  58. Castriconi R, Dondero A, Negri F, et al. Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur J Immunol. 2007;37:3190–6.

    Article  PubMed  CAS  Google Scholar 

  59. Fernández L, Portugal R, Valentín J, et al. In vitro natural killer cell immunotherapy for medulloblastoma. Front Oncol. 2013;3(94):1–7.

    Google Scholar 

  60. Martin A, Nirschl C, Polanczyk M, et al. MYC amplification status influences tumor immune evasion in medulloblastoma. Neuro-Oncol. 2013;15 suppl 1:15––16 [Abstract].

  61. Mulhern KR, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005;23(24):5511–9.

    Article  PubMed  Google Scholar 

  62. Sklar CA, Constine LS. Chronic neuroendocrinologic sequelae of radiation therapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1113–21.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Allison M. Martin, Eric Raabe, Charles Eberhart, and Kenneth J. Cohen declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bloomberg 11379, 1800 Orleans Street, Baltimore, MD, 21287, USA

    Allison M. Martin MD, Eric Raabe MD, PhD, Charles Eberhart MD, PhD & Kenneth J. Cohen MD, MBA

Authors
  1. Allison M. Martin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Raabe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles Eberhart MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenneth J. Cohen MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth J. Cohen MD, MBA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martin, A.M., Raabe, E., Eberhart, C. et al. Management of Pediatric and Adult Patients with Medulloblastoma. Curr. Treat. Options in Oncol. 15, 581–594 (2014). https://doi.org/10.1007/s11864-014-0306-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-014-0306-4

Keywords

Search

Navigation